These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 22416841)

  • 1. Dose as instrumental variable in exposure-safety analysis using count models.
    Wang J
    J Biopharm Stat; 2012; 22(3):565-81. PubMed ID: 22416841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determining causal exposure-response relationships with randomized concentration-controlled trials.
    Wang J
    J Biopharm Stat; 2014; 24(4):874-92. PubMed ID: 24697561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian population modeling of phase I dose escalation studies: Gaussian process versus parametric approaches.
    Russu A; Poggesi I; Gomeni R; De Nicolao G
    IEEE Trans Biomed Eng; 2011 Nov; 58(11):3156-64. PubMed ID: 21846598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A conditional maximized sequential probability ratio test for pharmacovigilance.
    Li L; Kulldorff M
    Stat Med; 2010 Jan; 29(2):284-95. PubMed ID: 19941282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case study of modeling and exposure-response prediction for count data.
    Quan H; Mao X; Wei L; Wang L
    J Biopharm Stat; 2014; 24(5):1073-90. PubMed ID: 24914574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2010 Sep; 20(5):1026-42. PubMed ID: 20721789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying potential adverse events dose-response relationships via Bayesian indirect and mixed treatment comparison models.
    Fu H; Price KL; Nilsson ME; Ruberg SJ
    J Biopharm Stat; 2013; 23(1):26-42. PubMed ID: 23331219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extreme value modelling of laboratory safety data from clinical studies.
    Southworth H; Heffernan JE
    Pharm Stat; 2012; 11(5):361-6. PubMed ID: 22684727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethically attractive dose-finding designs for drugs with a narrow therapeutic index.
    Lledó-García R; Hennig S; Nyberg J; Hooker AC; Karlsson MO
    J Clin Pharmacol; 2012 Jan; 52(1):29-38. PubMed ID: 21228403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Test hysteresis in pharmacokinetic/pharmacodynamic relationship with mixed-effect models: an instrumental model approach.
    Wang J; Li W
    J Biopharm Stat; 2014; 24(2):326-43. PubMed ID: 24605972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian population approaches to the analysis of dose escalation studies.
    Russu A; De Nicolao G; Poggesi I; Neve M; Gomeni R
    Comput Methods Programs Biomed; 2012 Aug; 107(2):189-201. PubMed ID: 21764475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous confidence bands for nonlinear regression models with application to population pharmacokinetic analyses.
    Gsteiger S; Bretz F; Liu W
    J Biopharm Stat; 2011 Jul; 21(4):708-25. PubMed ID: 21516565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future of toxicology--low-dose toxicology and risk--benefit analysis.
    Rietjens IM; Alink GM
    Chem Res Toxicol; 2006 Aug; 19(8):977-81. PubMed ID: 16918235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Logarithmic dose transformation in epidemiologic dose-response analysis: use with caution.
    Ginevan ME; Watkins DK
    Regul Toxicol Pharmacol; 2010 Nov; 58(2):336-40. PubMed ID: 20655968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-stage instrumental variable methods for estimating the causal odds ratio: analysis of bias.
    Cai B; Small DS; Have TR
    Stat Med; 2011 Jul; 30(15):1809-24. PubMed ID: 21495062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulation study of instrumental variable approaches with an application to a study of the antidiabetic effect of bezafibrate.
    Cai B; Hennessy S; Flory JH; Sha D; Ten Have TR; Small DS
    Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():114-20. PubMed ID: 22552986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poisson regression analysis of ungrouped data.
    Loomis D; Richardson DB; Elliott L
    Occup Environ Med; 2005 May; 62(5):325-9. PubMed ID: 15837854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating potential benefits of dose-exposure-response modeling for dose finding.
    Hsu CH
    Pharm Stat; 2009; 8(3):203-15. PubMed ID: 19629954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.